Current Urology Reports

, Volume 14, Issue 5, pp 435–441 | Cite as

β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Abstract

The new information generated over the last decade on the physiology/pharmacology of the normal bladder and on the pathophysiology of the overactive bladder has resulted in the introduction of a new therapeutic principle, β3-adrenoceptor (AR) agonism, and the approval of mirabegron, a selective agonist at β3-ARs. It may be asked in what respects the β3-AR agonists as a group, and mirabegron in particular, differ from the antimuscarinics, and what can clinically be gained by the β3-AR agonists. In this short review, the mechanisms of action, clinical efficacy, and adverse effect profiles of the two groups of drugs are compared and discussed.

Keywords

Antimuscarinics Mirabegron Mechanisms of action Clinical efficacy Adverse effect profile 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults:AUA/SUFU guideline. American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. J Urol. 2012;188(6 Suppl):2455–63.PubMedCrossRefGoogle Scholar
  2. 2.
    Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012;62(6):1130–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Novara G, Galfano A, Secco S, et al. Systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–63.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Incontinence. ed by AbramsP, Cardozo L, Khoury A, Wein A. 5th International Consultation on Incontinence, Paris February 2012, ICUD-EAU 2013:625–728. Up-to-date review of current treatments.Google Scholar
  6. 6.
    Andersson KE, Martin N, Nitti V. Selective β3-Adrenoceptor Agonists in the Treatment of the Overactive Bladder. J Urol. 2013b Feb 28. [Epub ahead of print]Google Scholar
  7. 7.
    Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res. 2009;59(4):221–34.PubMedCrossRefGoogle Scholar
  8. 8.
    Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202:319–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.PubMedCrossRefGoogle Scholar
  10. 10.
    Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59(3):377–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56(5):810–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder. Int J Urol. 2013;20(1):21–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004;93(4):478–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Kanai A, Andersson KE. Bladder afferent signaling: recent findings. J Urol. 2010;183(4):1288–95.PubMedCrossRefGoogle Scholar
  15. 15.
    Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Iggo A. Tension receptors in the stomach and the urinary bladder. J Physiol. 1955;128(3):593–607.PubMedGoogle Scholar
  17. 17.
    Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98(6):1310–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Svalø J, Nordling J, Bouchelouche K, et al. The novel β(3)-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol. 2012;699(1–3):101–5.PubMedGoogle Scholar
  20. 20.
    Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective β(3)-adrenoceptor agonistmirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec 14. [Epub ahead of print]Google Scholar
  21. 21.
    Hatanaka T, Ukai M, Watanabe M, et al. Effect of mirabegron, a novel β(3)-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):71–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110(2 Pt 2):E132–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a β3 adrenoreceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn. 2010;29:771–6.PubMedCrossRefGoogle Scholar
  24. 24.
    • Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62(6):1165–73. Nice demonstration of mirabegron effects on bladder Aδ - and C-fiber afferents.PubMedCrossRefGoogle Scholar
  25. 25.
    Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Andersson KE, Fullhase C, Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008;9(6):459–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailibility of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838–50.PubMedCrossRefGoogle Scholar
  28. 28.
    Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic Properties of Mirabegron, a β(3)-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women. Clin Ther. 2012;34(10):2144.PubMedCrossRefGoogle Scholar
  29. 29.
    Füllhase C, Soler R, Westerling-Andersson K, Andersson KE. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction. Neurourol Urodyn. 2011;30(7):1382–7.PubMedGoogle Scholar
  30. 30.
    Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815.PubMedCrossRefGoogle Scholar
  31. 31.
    Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist. Xenobiotica. 2012 Apr 18. [Epub ahead of print]Google Scholar
  32. 32.
    Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012 Jul 27. [Epub ahead of print]Google Scholar
  33. 33.
    Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183:1077–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.PubMedCrossRefGoogle Scholar
  36. 36.
    Gomes T, Juurlink DN, Mamdani MM. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clin Pharmacol. 2012;68(1):97–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Lee YS, Choo MS, Lee JY, Oh SJ, Lee KS. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011;65(9):997–1004.PubMedCrossRefGoogle Scholar
  38. 38.
    •• Uvin P, Boudes M, Franken J, et al. Why anticholinergics fail: Oxybutynin and fesoterodine induce a shift from muscarinergic to purinergic transmission in the rat bladder. Eur Urol Suppl. 2013;12:e441. Interesting preliminary report suggestion tolerance development to muscarinic receptor blockade.CrossRefGoogle Scholar
  39. 39.
    Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013 Mar 8. [Epub ahead of print]Google Scholar
  40. 40.
    Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013 Feb 19. [Epub ahead of print]Google Scholar
  41. 41.
    Nitti VW, Auerbach S, Martin N, et al. Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder. J Urol. 2013;189(4):1388–95.PubMedCrossRefGoogle Scholar
  42. 42.
    Khullar V, Amarenco G, Angulo JC, et al. Efficacy and Tolerability of Mirabegron, a β(3)-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial. Eur Urol. 2013;63(2):283–95.PubMedCrossRefGoogle Scholar
  43. 43.
    Van Kerrebroeck P, Barkin Z, Castro-Diaz D, et al. Randomised, double-blind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). Beijing: Presented at the International Continence Society Meeting; 2012.Google Scholar
  44. 44.
    •• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. The first long-term study of mirabegron with a toterodine treatment arm.PubMedCrossRefGoogle Scholar
  45. 45.
    Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;18:1. CD005429.Google Scholar
  46. 46.
    Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011;6(2):e16718.PubMedCrossRefGoogle Scholar
  47. 47.
    Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007;100(5):1007–14.Google Scholar
  48. 48.
    Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharm. 2011;72:186–96.CrossRefGoogle Scholar
  49. 49.
    Nitti V, Rosenberg S, Mitcheson HD, et al. Randomized, multicenter phase II study evaluating the urodynamic safety of mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outlet. J Urol. 2012;187(4 suppl):e756.CrossRefGoogle Scholar
  50. 50.
    Mirabegron prescribing information. http://www.us.astellas.com/docs/myrbetriq-full-pi.pdf. Accessed 1 May 2013.
  51. 51.
    • Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study. Clin Pharmacol Ther. 2012;92(6):696. Important documentation of cardiac effects of mirabegron.PubMedCrossRefGoogle Scholar
  52. 52.
    Rekik M, Rouget C, Palea S, et al. Effects of combining antimuscarinics and β3-adrenoceptor agonists on contractions induced by electrical field stimulation of rat isolated urinary bladder strips. Eur Urol Suppl. 2013;12:e440.CrossRefGoogle Scholar
  53. 53.
    Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - Efficacy results from a phase 2 study (Symphony). J Urol Suppl. 2013;189(4S):e803.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Institute for Regenerative MedicineWake Forest University School of MedicineWinston SalemUSA
  2. 2.Department of Urology, Wake Forest Baptist Medical CenterWinston SalemUSA

Personalised recommendations